全文获取类型
收费全文 | 144篇 |
免费 | 6篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 3篇 |
妇产科学 | 2篇 |
基础医学 | 14篇 |
口腔科学 | 1篇 |
临床医学 | 12篇 |
内科学 | 72篇 |
皮肤病学 | 2篇 |
特种医学 | 4篇 |
外科学 | 4篇 |
综合类 | 1篇 |
预防医学 | 16篇 |
眼科学 | 5篇 |
药学 | 5篇 |
中国医学 | 2篇 |
肿瘤学 | 4篇 |
出版年
2023年 | 1篇 |
2022年 | 11篇 |
2021年 | 26篇 |
2020年 | 15篇 |
2019年 | 4篇 |
2018年 | 7篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 1篇 |
2013年 | 10篇 |
2012年 | 12篇 |
2011年 | 18篇 |
2010年 | 10篇 |
2009年 | 4篇 |
2008年 | 6篇 |
2007年 | 3篇 |
2006年 | 2篇 |
2005年 | 1篇 |
2004年 | 3篇 |
2003年 | 1篇 |
2002年 | 2篇 |
2001年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1990年 | 1篇 |
1983年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有150条查询结果,搜索用时 0 毫秒
1.
Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. 总被引:13,自引:0,他引:13
Winnie Yeo Paul K S Chan Wing M Ho Benny Zee Kwok C Lam Kenny I K Lei Anthony T C Chan Tony S K Mok Jam J Lee Thomas W T Leung Sheng Zhong Philip J Johnson 《Journal of clinical oncology》2004,22(5):927-934
PURPOSE: For cancer patients receiving cytotoxic chemotherapy, hepatitis B virus (HBV) reactivation is a well described complication resulting in varying degrees of liver damage. The objectives of this study were to assess the efficacy of the antiviral agent lamivudine in reducing the incidence of HBV reactivation and diminishing morbidity and mortality of cancer patients with chronic HBV infection during chemotherapy. PATIENTS AND METHODS: Two groups were compared in this nonrandomized study. The prophylactic lamivudine group consisted of 65 patients in a phase II study who were treated with lamivudine before and until 8 weeks after discontinuing chemotherapy. The historical controls consisted of 193 consecutive patients who underwent chemotherapy without prophylactic lamivudine. Significant prognosticators for the development of HBV reactivation were determined based on data from the controls. Potential confounding factors were identified between the two groups. The outcomes were compared. RESULTS: In the controls, lymphoma and anthracycline usage were factors identified to be associated with reactivation. The two groups were comparable in most baseline characteristics, although in the prophylactic lamivudine group, there were significantly more patients with lymphoma and receiving anthracyclines. In the prophylactic lamivudine group, there was significantly less HBV reactivation (4.6% v 24.4% in the controls; P <.001), fewer incidences of hepatitis (17.5% v 44.6%; P <.0001) that were less severe (4.8% v 18.7%; P =.0005), and less disruption of chemotherapy (15.4% v 34.6%; P =.0029). The reduction in overall mortality was not statistically different. CONCLUSION: Prophylactic lamivudine significantly reduced the incidence of HBV reactivation and the overall morbidity of cancer patients undergoing chemotherapy. 相似文献
2.
Huanhuan Miao Changhong Zou Shijie Yang YookChin Chia Minh Van Huynh Guru Prasad Sogunuru Jam Chin Tay TzungDau Wang Kazuomi Kario Yuqing Zhang 《Journal of clinical hypertension (Greenwich, Conn.)》2022,24(9):1218
Hypertension is highly prevalent worldwide and is the major risk factor for heart failure (HF). More than half of the patients with HF in Asia suffer from hypertension. According to the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America HF guideline, there are four stages of HF, including at risk for HF (stage A), pre‐HF (stage B), symptomatic HF (stage C), and advanced HF (stage D). Given the high prevalence of hypertension as well as HF and the stronger association between hypertension and cardiovascular diseases in Asians compared to the west, measures to prevent and alleviate the progression to clinical HF, especially controlling the blood pressure (BP), are of priority for Asian populations. After reviewing evidence‐based studies, we propose a BP target of less than 130/80 mmHg for patients at stages A, B, and C. However, relatively higher BP may represent an opportunity to maximize guideline‐directed medical therapy (GDMT), which could potentially result in a better prognosis for patients at stage D. Traditional antihypertensive drugs are the cornerstones for the management of hypertension at stages A and B. Notably, calcium channel blockers (CCBs) are inferior to other drug classes for the preventing of HF, whereas diuretics are superior to others. For patients at stage C, GDMT is essential which also helps the control of BP. In particular, sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are newer therapies recommended for the treatment of HF and presumably even in hypertension to prevent HF. Regarding patients at stage D, GDMT is also recommended if tolerable and measures should be taken to improve hemodynamics. 相似文献
3.
HuiChun Huang Haomin Cheng YookChin Chia Yan Li Huynh Van Minh Saulat Siddique Apichard Sukonthasarn Jam Chin Tay Yuda Turana Narsingh Verma Kazuomi Kario TzungDau Wang 《Journal of clinical hypertension (Greenwich, Conn.)》2022,24(9):1187
Recent trials have demonstrated the efficacy and safety of percutaneous renal sympathetic denervation (RDN) for blood pressure (BP)‐lowering in patients with uncontrolled hypertension. Nevertheless, major challenges exist, such as the wide variation of BP‐lowering responses following RDN (from strong response to no response) and lack of feasible and reproducible peri‐procedural predictors for patient response. Both animal and human studies have demonstrated different patterns of BP responses following renal nerve stimulation (RNS), possibly related to varied regional proportions of sympathetic and parasympathetic nerve tissues along the renal arteries. Animal studies of RNS have shown that rapid electrical stimulation of the renal arteries caused renal artery vasoconstriction and increased norepinephrine secretion with a concomitant increase in BP, and the responses were attenuated after RDN. Moreover, selective RDN at sites with strong RNS‐induced BP increases led to a more efficient BP‐lowering effect. In human, when RNS was performed before and after RDN, blunted changes in RNS‐induced BP responses were noted after RDN. The systolic BP response induced by RNS before RDN and blunted systolic BP response to RNS after RDN, at the site with maximal RNS‐induced systolic BP response before RDN, both correlated with the 24‐h ambulatory BP reductions 3–12 months following RDN. In summary, RNS‐induced BP changes, before and after RDN, could be used to assess the immediate effect of RDN and predict BP reductions months following RDN. More comprehensive, large‐scale and long term trials are needed to verify these findings. 相似文献
4.
WeiChieh Huang YenHung Lin VinCent Wu ChenHuan Chen Saulat Siddique YookChin Chia Jam Chin Tay Guruprasad Sogunuru HaoMin Cheng Kazuomi Kario 《Journal of clinical hypertension (Greenwich, Conn.)》2022,24(9):1194
Arterial hypertension is a major risk factor for cardiovascular disease. The prevalence of primary aldosteronism (PA) ranges from 5% to 10% in the general hypertensive population and is regarded as one of the most common causes of secondary hypertension. There are two major causes of PA: bilateral adrenal hyperplasia and aldosterone‐producing adenoma. The diagnosis of PA comprises screening, confirmatory testing, and subtype differentiation. The Endocrine Society Practice Guidelines for the diagnosis and treatment of PA recommends screening of patients at an increased risk of PA. These categories include patients with stage 2 and 3 hypertension, drug‐resistant hypertension, hypertensive with spontaneous or diuretic‐induced hypokalemia, hypertension with adrenal incidentaloma, hypertensive with a family history of early onset hypertension or cerebrovascular accident at a young age, and all hypertensive first‐degree relatives of patients with PA. Recently, several studies have linked PA with obstructive sleep apnea and atrial fibrillation unexplained by structural heart defects and/or other conditions known to cause the arrhythmia, which may be partly responsible for the higher rates of cardiovascular and cerebrovascular accidents in patients with PA. The aim of this review is to discuss which patients should be screened for PA, focusing not only on well‐established guidelines but also on additional groups of patients with a potentially higher prevalence of PA, as has been reported in recent research. 相似文献
5.
6.
Yuda Turana Jeslyn Tengkawan Yook Chin Chia Michael Nathaniel JiGuang Wang Apichard Sukonthasarn ChenHuan Chen Huynh Van Minh Peera Buranakitjaroen Jinho Shin Saulat Siddique Jennifer M. Nailes Sungha Park Boon Wee Teo Jorge Sison Arieska Ann Soenarta Satoshi Hoshide Jam Chin Tay Guru Prasad Sogunuru Yuqing Zhang Narsingh Verma TzungDau Wang Kazuomi Kario the HOPE Asia Network 《Journal of clinical hypertension (Greenwich, Conn.)》2021,23(3):513
Stroke is the primary cause of disability and vascular death worldwide, including Asia. Asian characteristics that differ from the West lead to higher stroke incidence. Stroke epidemiology studies in Asia have shown varying levels of mortality, incidence, prevalence, and burden of disease. Hypertension is the most prevalent risk factor found in Asia. Besides ethnicity that is associated with stroke incidence, both systolic blood pressure, diastolic blood pressure, and blood pressure variability are positively correlated with stroke incidence. Post‐stroke cognitive impairment is one of the sequelae that affect one‐third of stroke survivors and has become a significant public health concern that is often neglected despite its increasing prevalence. Therefore, it is very important to prevent recurrence by treating stroke optimally and effectively. Increasing awareness and treatment adherence to hypertension, the leading risk factor for stroke, became the main goal in several countries in Asia. 相似文献
7.
Arieska Ann Soenarta Peera Buranakitjaroen Yook‐Chin Chia Chen‐Huan Chen Jennifer Nailes Satoshi Hoshide Huynh Van Minh Sungha Park Jinho Shin Saulat Siddique Jorge Sison Guru Prasad Sogunuru Apichard Sukonthasarn Jam Chin Tay Boon Wee Teo Yuda Turana Narsingh Verma Tzung‐Dau Wang Yu‐Qing Zhang Ji‐Guang Wang Kazuomi Kario 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(3):423-430
Cardiovascular Disease (CVD) is the leading cause of deaths worldwide, contributing to about 30% of all deaths. Half of the cases of CVD are estimated in Asia, the world's most populous continent. Hypertension, a major modifiable risk factor for CVD, results in more deaths than any other CV risk factors in the Asian regions. The total number of patients with hypertension is likely to grow as the population ages. The proportion of the elderly population aged 65 years or more in Asia is expected to increase from 7.4% in 2015 to 10.9% in 2030. It is important to note that more than half (54%) of the world's population live in Asia. Aside of being the biggest single risk factor for global deaths, hypertension is also an important precursor and most common risk factor of heart failure (HF). An increase in HF prevalence is clearly related to the rapid epidemiological transition caused by changes in lifestyle in Asian countries. However, the availability of data on HF burden and health care delivery is limited in Asia compared with Europe and North America. This reality has driven the working group of Asian experts for example the HOPE Asia Network to concentrate on hypertension as risk factors for CVD, with the mission to improve the management of hypertension resulting in organ protection toward a goal of achieving “ZERO” CV event in Asia. This paper aims to give an overview regarding the heart problems caused by hypertension in Asia, focus on HF. 相似文献
8.
Jinho Shin Kazuomi Kario Yook‐Chin Chia Yuda Turana Chen‐Huan Chen Peera Buranakitjaroen Romeo Divinagracia Jennifer Nailes Satoshi Hoshide Saulat Siddique Jorge Sison Arieska Ann Soenarta Guru Prasad Sogunuru Jam Chin Tay Boon Wee Teo Yu‐Qing Zhang Sungha Park Huynh Van Minh Tomoyuki Kabutoya Narsingh Verma Tzung‐Dau Wang Ji‐Guang Wang 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(3):384-390
Ambulatory blood pressure monitoring (ABPM) can measure 24‐hour blood pressure (BP), including nocturnal BP and diurnal variations. This feature of ABPM could be of value in Asian populations for preventing cardiovascular events. However, no study has yet investigated regarding the use of ABPM in actual clinical settings in Asian countries/regions. In this study, 11 experts from 11 countries/regions were asked to answer questionnaires regarding the use of ABPM. We found that its use was very limited in primary care settings and almost exclusively available in referral settings. The indications of ABPM in actual clinical settings were largely similar to those of home BP monitoring (HBPM), that is, diagnosis of white‐coat or masked hypertension and more accurate BP measurement for borderline clinic BP. Other interesting indications, such as nighttime BP patterns, including non‐dipper BP, morning BP surge, and BP variability, were hardly adopted in daily clinical practice. The use of ABPM as treatment guidance for detecting treated but uncontrolled hypertension in the Asian countries/regions didn't seem to be common. The barrier to the use of ABPM was primarily its availability; in referral centers, patient reluctance owing to discomfort or sleep disturbance was the most frequent barrier. ABPM use was significantly more economical when it was reimbursed by public insurance. To facilitate ABPM use, more simplified indications and protocols to minimize discomfort should be sought. For the time being, HBPM could be a reasonable alternative. 相似文献
9.
Kazuomi Kario Yook‐Chin Chia Apichard Sukonthasarn Yuda Turana Jinho Shin Chen‐Huan Chen Peera Buranakitjaroen Jennifer Nailes Satoshi Hoshide Saulat Siddique Jorge Sison Arieska Ann Soenarta Guru Prasad Sogunuru Jam Chin Tay Boon Wee Teo Yu‐Qing Zhang Sungha Park Huynh Van Minh Naoko Tomitani Tomoyuki Kabutoya Narsingh Verma Tzung‐Dau Wang Ji‐Guang Wang 《Journal of clinical hypertension (Greenwich, Conn.)》2020,22(3):331-343
The Hypertension Cardiovascular Outcome Prevention and Evidence in Asia (HOPE Asia) Network was set up to improve the management of hypertension in Asia with the ultimate goal of achieving “zero” cardiovascular events. Asia is a diverse continent, and the prevalence of hypertension has increased over the last 30 years. There are a number of Asia‐specific features of hypertension and hypertension‐related cardiovascular complications, which means that a region‐specific approach is needed. White‐coat hypertension will become more of an issue over time as Asian populations age, and masked hypertension is more prevalent in Asian than in Western countries. Identifying and treating masked hypertension is important to reduce cardiovascular risk. Abnormal patterns of blood pressure (BP) variability common in Asia include exaggerated early morning BP surge and nocturnal hypertension. These are also important cardiovascular risk factors that need to be managed. Home blood pressure monitoring (HBPM) is an important tool for detecting white‐coat and masked hypertension, and monitoring BP variability, and practices in Asia are variable. Use of HBPM is important given the Asia‐specific features of hypertension, and strategies are needed to improve and standardize HBPM usage. Development of HBPM devices capable of measuring nocturnal BP along with other information and communication technology‐based strategies are key developments in the widespread implementation of anticipation medicine strategies to detect and prevent cardiovascular events in patients with hypertension. Region‐wide differences in hypertension prevalence, control, and management practices in Asia highlight the importance of information sharing to facilitate best practices. 相似文献
10.
Coronary artery fistula is a rare abnormality of coronary circulation. It is mostly congenital but acquired forms can also occur. Fistulae are usually asymptomatic and can sometimes be visualized during cardiac imaging such as transthoracic echocardiogram, cardiac magnetic resonance imaging, coronary computed tomography angiography and coronary angiography. 相似文献